leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...104105106107108109110111112113114...235236»
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Journal:  Implementation of an Outpatient HD-MTX Initiative. (Pubmed Central) -  Feb 8, 2022   
    Methotrexate (MTX) a folate antagonist is often given in high doses (≥500 mg/m) to treat a variety of disease processes...The outpatient protocol involved continuous IV sodium bicarbonate, along with oral leucovorin and acetazolamide...This study largely details the development of this protocol and its initial safety evaluation. More work needs to be done to assess its feasibility on a larger number of patients who receive more cycles in the outpatient setting.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer. (Pubmed Central) -  Feb 8, 2022   
    mFOLFOX6 or SOX plus cetuximab was administered to 12 patients with the wild-type RAS gene and FOLFOXIRI or SOXIRI to 18 patients with mutant-type RAS...The response rate of NAC and the proportion of histological anti-tumor effect grade ≥ 2 were 56.7% and 46.7%, respectively. NAC was considered to be a safe, feasible treatment option for LARC.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial termination, Monotherapy, Metastases:  Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) -  Feb 7, 2022   
    P2,  N=2, Terminated, 
    Active, not recruiting --> Completed Suspended --> Terminated; Administrative change
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Review, Journal:  Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. (Pubmed Central) -  Feb 5, 2022   
    Current treatment regimens mainly comprise the cytotoxic agents gemcitabine and FOLFIRINOX...In this review we describe the 11 most promising transmembrane proteins, carefully selected after a thorough literature search. Favorable features and potential applications of each target, as well as the results of the preclinical and clinical studies conducted in the past ten years, are discussed in detail.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. (Pubmed Central) -  Feb 5, 2022   
    Nearly 20% of patients with locally advanced PDAC responded sufficiently to induction FOLFIRINOX to undergo resection, which was associated with improved OS compared to patients that did not undergo resection. Patients with stable disease who remain unresectable represent a group of patients with locally advanced PDAC who may benefit from optimization of additional nonoperative treatment.
  • ||||||||||  Vyloy (zolbetuximab-clzb) / Astellas
    Biomarker, Enrollment open, Monotherapy:  ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) -  Feb 4, 2022   
    P2,  N=116, Recruiting, 
    By using the model for intervention, it was found that prophylactic treatment with butyrate might be a valuable strategy for prophylactic mucositis prevention. Active, not recruiting --> Recruiting
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
    Journal:  Up-to-date role of aflibercept in the treatment of colorectal cancer. (Pubmed Central) -  Feb 2, 2022   
    The results of the VELOUR study showed that the addition of aflibercept to second-line FOLFIRI improved OS and progression-free survival (PFS).Areas covered: A literature review of published clinical studies was performed in order to discuss the clinical data on aflibercept in mCRC from early drug development to real-world data.Expert Opinion: The combination of aflibercept with FOLFIRI provides a statistical improvement in OS and in all the efficacy endpoints analysed in the VELOUR trial, showing efficacy independently on time to progression, molecular status, prior biological treatment, or age. Further studies are needed to find new biomarkers and molecular characterization in order to better select patients that could benefit from this treatment.
  • ||||||||||  pegilodecakin (LY3500518) / Eli Lilly
    Journal:  Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). (Pubmed Central) -  Feb 1, 2022   
    P1
    Here we report on all enrolled patients from cohort C. Heavily pretreated patients were treated with pegilodecakin (self-administered subcutaneously daily at 2.5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression...Conclusions Pegilodecakin+FOLFOX had an acceptable tolerability profile in PDAC, with no substantial irAEs seen, and promising efficacy with the combination yielding a 2-year OS of 24% (95% CI 10-42). These data led to the phase 3 study with pegilodecakin+FOLFOX as second-line therapy of PDAC (SEQUOIA).
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal, HEOR:  Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. (Pubmed Central) -  Feb 1, 2022   
    QoL is very good in most LAPC patients with disease control after FOLFIRINOX, measured with validated questionnaires and Actiwatch registration. The fear of clinical deterioration after FOLFIRINOX is not substantiated by this study and should not be a reason to refrain from treatment.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Journal:  Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. (Pubmed Central) -  Feb 1, 2022   
    Abnormal CA19-9 values at the time of surgery negatively impacted both OS (HR 2.46, 95%CI 1.28-4.72, p<0.007) and PFS (HR 2.192, 95%CI 1.143-4.201, p=0.018) following IRE. Age, CA 19-9 response, avoidance of pre-IRE radiation, and FOLFIRINOX plus gemcitabine/abraxane induction chemotherapy are prominent factors to consider when referring or selecting LAPC patients to undergo IRE.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Trial completion date, Trial primary completion date, Combination therapy:  FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (clinicaltrials.gov) -  Feb 1, 2022   
    P2/3,  N=180, Active, not recruiting, 
    Age, CA 19-9 response, avoidance of pre-IRE radiation, and FOLFIRINOX plus gemcitabine/abraxane induction chemotherapy are prominent factors to consider when referring or selecting LAPC patients to undergo IRE. Trial completion date: Oct 2021 --> Mar 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    MULTIPLE MECHANISMS OF 5-FLOUROURACIL (5-FU)-ASSOCIATED CHEST PAIN IN A PATIENT WITH METASTATIC SIGMOID CANCER (eAbstract site) -  Jan 28, 2022 - Abstract #ACC2022ACC_5144;    
    We describe a patient who presents with recurrent chest pain on FOLFOX, and multimodality imaging suggestive of independent mechanisms of 5-FU cardiotoxicity.Case: A 43 year-old woman with metastatic sigmoid cancer on FOLFOX and cetuximab presented with positional chest pain 4 days after cycle 7...The patient was treated with colchicine and symptoms resolved... Independent mechanisms of 5-FU-associated chest pain were implicated in our patient through multimodality imaging: pericarditis and microvascular endothelial dysfunction.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    A RARE CASE OF LERICHE SYNDROME IN A PATIENT WITH COLON CANCER: CASE REPORT AND LITERATURE REVIEW (eAbstract site) -  Jan 28, 2022 - Abstract #ACC2022ACC_1980;    
    Retrospective data analysis shows that only 8.3% of patients with Aorto-iliac occlusion or stenosis had colorectal cancer. Our case highlights the association of this syndromic presentation in patients with colon cancer and is a reminder for clinicians to suspect its occurrence in case of leg pain or absent peripheral pulses.
  • ||||||||||  5-fluorouracil / Generic mfg.
    PREVENTING LIFE-THREATENING 5-FLUOROURACIL CARDIOTOXICITY (Complex Clinical Cases Moderated Poster Theater 2_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_1203;    
    Multidisciplinary discussion between cardiologists and oncologists is recommended for co-management of reversible 5-FU associated cardiotoxicity. After CAD risk stratification and treatment per ACC/AHA guidelines, empiric treatment with calcium channel blockers and/or nitrates may allow patients with suspected coronary vasospasm from 5-FU to continue this vital chemotherapy.
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Jan 28, 2022   
    P3,  N=300, Recruiting, 
    After CAD risk stratification and treatment per ACC/AHA guidelines, empiric treatment with calcium channel blockers and/or nitrates may allow patients with suspected coronary vasospasm from 5-FU to continue this vital chemotherapy. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  Q-Force (quercetin) / Quercegen, Temple University
    Quercetin and Azithromycin combination arrest Toxoplasma gondii growth (In-Person Room (Virtual Room)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_13239;    
    Treatments of toxoplasmosis involve a combination of drugs such as sulfadiazine plus folinic acid and pyrimethamine...All compounds were not toxic to Vero cells. Further research is ongoing to decipher their mechanism of action and interaction using biochemical and in silico studies.Keywords: Quercetin; Azithromycin; Inhibition; Toxoplasma gondii; Growth
  • ||||||||||  cisplatin / Generic mfg., paclitaxel / Generic mfg.
    Chemoresistant Gestational Trophoblastic Neoplasia: Mansoura Experience () -  Jan 27, 2022 - Abstract #BGICC2022BGICC_179;    
    El-lamieet from Ain Shams University, recommended incorporation of paclitaxel in the third-line treatment of resistant GTN... A collaboration of efforts is needed from gynecologists, medical oncologists, radiologists, pathologists, and others to optimally treat patients with chemoresistant GTN.